Articles

Behavioural economics: a powerful tool to examine decision-making

22nd August 2014

Behavioural economics: a powerful tool to examine decision-makingRebecca Marshall-Clarke

Behavioural economics can be used to frame market researchers' questions so as to ensure respondents' answers are the most accurate and unbiased as possible, thereby informing more effective brand campaigns.Isn't... Read more

Sovaldi and the politics of high-priced drugs: are we asking the right…

21st August 2014

Sovaldi and the politics of high-priced drugs: are we asking the right questions?Daniel Liden and Yin Ho

There has been a lot of discussion about the high price of Gilead's Hepatitis C drug Sovaldi, and a variety of strong opinions expressed. But are agencies around the world... Read more

Bioinformatics: the next big thing in life sciences

20th August 2014

Bioinformatics: the next big thing in life sciencesWill Spooner

Bioinformatics is starting to show its strength as a tool to interpret and analyse vast amounts of complex data in the search for new drugs.While the field of bioinformatics has... Read more

The future of the UK pharma market: Part One: the global context

19th August 2014

The future of the UK pharma market:  Part One: the global contextSarah Rickwood

The UK's reputation as a problematic, slow uptake market doesn't capture the whole picture – it is a pioneer in many respects, and still a key market for new product... Read more

News

Pfizer casting elsewhere for overseas M&A?

22nd August 2014

Pfizer casting elsewhere for overseas M&A?Staff reporter

A series of positive pipeline updates could make the asking price for AstraZeneca (AZ) very steep if Pfizer makes another takeover attempt in November.Facing that situation - and likely continued... Read more

Lilly lifted by psoriasis results

22nd August 2014

Lilly lifted by psoriasis resultsAndrew McConaghie

Lilly has unveiled strong phase III results for its psoriasis drug ixekizumab, showing it to be superior to Pfizer's Enbrel (etanercept) and placebo on all skin clearance.The company disclosed top-line... Read more

AstraZeneca extends cancer gene sequencing collaborations

21st August 2014

AstraZeneca extends cancer gene sequencing collaborationsLinda Banks

AstraZeneca (AZ) is to collaborate with gene sequencing company, Illumina, to develop its next generation sequencing (NGS) platform for companion diagnostic tests for use with AZ's oncology portfolio.The agreement represents... Read more

Wellcome Trust to invest in Ebola research

21st August 2014

Wellcome Trust to invest in Ebola researchAndrew McConaghie

A multi-million-pound emergency fund for research aimed at containing the Ebola epidemic in West Africa and future outbreaks of infectious disease has been announced by the Wellcome Trust.The UK's Wellcome... Read more

Audio & Video

Patient Opinion Leaders: Andrew Schorr

 

As a cancer survivor and passionate patient advocate, Andrew Schorr typifies the concept of a Patient Opinion Leader (POL). He is a contributor to the... View more

View the recorded webinar - The future o…

WEBINAR COVER smaller


The global pharmaceutical market passes a significant milestone in 2014: reaching one trillion US dollars in total value. IMS Health... View more

Rare Disease Day tweetchat

 

To view a full transcript of the discussion from this #hcsmeu tweetchat held on 28th February 2014 please click View more

Is there common ground for engagement be…

Doctors net webinar

 

The growth of online networks for doctors has been accompanied by recognition from the pharmaceutical industry that these digital meeting grounds can be... View more

White Papers

Diabetes in France

Diabetes in FranceJanet Gunner

Analysis of open social media in relation to a particular disease area can provide useful intelligence on how different treatments and pharmaceutical companies are perceived, by both doctors and patients,... View info

Diabetes in Germany

Diabetes in GermanyJanet Gunner

Analysis of open social media in relation to a particular disease area can provide useful intelligence on how different treatments and pharmaceutical companies are perceived, by both doctors and patients,... View info

Connected data and the use of smartphone…

Connected data and the use of smartphone enabled apps in market researchPaul Mannu

Rapid growth in smartphone usage offers healthcare researchers a useful tool to gain better understanding of how patients and healthcare professionals actually behave on a daily basis. Inaccuracies can arise... View info

Diabetes in the UK

Diabetes in the UKJanet Gunner

Analysis of open social media in relation to a particular disease area can provide useful intelligence on how different treatments and pharmaceutical companies are perceived, by both doctors and patients,... View info

Further News & Articles

Novartis invests in novel stem cell technology

Novartis is to invest $35 million in Israeli company Gamida Cell, to develop novel stem cell treatment NiCord... Read more

News

NICE yes for Revlimid after price limit

NICE has recommended Celgene's Revlimid (lenalidomide) as an option for treating myelodysplastic syndromes.Read more

News

Eisai files Fycompa for wider epilepsy use

Eisai is looking to extend the use of its epilepsy treatment Fycompa into use as adjunctive treatment of serious... Read more

News

Diabetes drug Basaglar receives tentative FDA approval

The FDA has granted tentative approval for Basaglar (insulin glargine injection), produced by Eli Lilly and Boeh... Read more

News

Bioscience would lose out in an independent Scotland, warns minister

A UK government science minister has warned that Scotland's life sciences sector would lose out if the country d... Read more

News

Eisai ‘outraged’ by decision on epilepsy drug

A ruling in Germany which has found Eisai's epilepsy drug Fycompa to have no extra benefits to existing treat... Read more

News